FortuneRock Given Go-Ahead to Begin China Trials of Long-Acting Interferon
06:00 EDT 23 Aug 2012 | ChinaBio Today
FortuneRock of the US has received SFDA approval to begin China clinical trials of its long-acting formulation of Interferon-α2a. Fortune developed the product using its proprietary fusion technology to create a drug that is administered eve..
Original Article: FortuneRock Given Go-Ahead to Begin China Trials of Long-Acting Interferon
More From BioPortfolio on "FortuneRock Given Go-Ahead to Begin China Trials of Long-Acting Interferon"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
